PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, solidifying its position as a leading player in the industry. With this funding, PlasmaGen has now raised over ₹600 crore to date, demonstrating the confidence of investors in its vision and capabilities.
PlasmaGen Biosciences is a pioneering company in the field of plasma fractionation, operating one of India’s five plasma fractionation facilities near Bengaluru. The company’s state-of-the-art facility is equipped with cutting-edge technology, enabling it to produce high-quality plasma-derived products that cater to the growing demand for life-saving therapies. PlasmaGen’s product portfolio includes a range of therapies for treating rare and debilitating diseases, such as hemophilia, immunodeficiency disorders, and neurological disorders.
The funding round was led by ViNS Bioproducts, a prominent player in the biotechnology industry. The investment is a testament to PlasmaGen’s commitment to delivering innovative and effective treatments to patients. The company’s strong research and development capabilities, combined with its robust manufacturing infrastructure, have enabled it to establish a significant presence in the global market.
PlasmaGen is backed by esteemed investors, including Eight Roads, FIL Capital, and F-Prime. These investors have been instrumental in supporting the company’s growth and expansion plans, providing strategic guidance and expertise to help PlasmaGen achieve its goals. With their continued support, the company is well-positioned to further strengthen its market presence and explore new opportunities for growth.
The Indian biotechnology sector has witnessed significant growth in recent years, driven by government initiatives, increasing investment, and a growing demand for innovative treatments. The sector is expected to continue its upward trajectory, with projections suggesting that it will reach $150 billion by 2025. PlasmaGen is well-placed to capitalize on this growth, with its strong foundation in plasma fractionation and its commitment to delivering high-quality products.
The company’s plasma fractionation facility near Bengaluru is a critical component of its operations, enabling it to produce a range of plasma-derived products. The facility is equipped with advanced technology, including state-of-the-art purification systems and quality control measures, ensuring that all products meet the highest standards of quality and safety. PlasmaGen’s commitment to quality and safety has earned it a reputation as a trusted and reliable partner in the biotechnology industry.
The funding raised by PlasmaGen will be utilized to further expand its operations, enhance its research and development capabilities, and explore new markets for its products. The company plans to invest in new technologies and infrastructure, enabling it to increase its production capacity and cater to the growing demand for plasma-derived products. Additionally, PlasmaGen will focus on developing new products and therapies, leveraging its expertise in plasma fractionation to address unmet medical needs.
In conclusion, PlasmaGen Biosciences’ ₹150 crore funding round is a significant milestone for the company, marking a major step forward in its growth and expansion plans. With a valuation of over ₹1,500 crore, PlasmaGen is poised to play a leading role in the Indian biotechnology sector, delivering innovative and effective treatments to patients across the globe. As the company continues to grow and expand its operations, it is likely to have a profound impact on the industry, driving innovation and advancement in the field of plasma fractionation.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
